NO20083838L - Anvendelse av KCNQ-apnere for a behandle eller redusere symptomene pa schizofreni - Google Patents

Anvendelse av KCNQ-apnere for a behandle eller redusere symptomene pa schizofreni

Info

Publication number
NO20083838L
NO20083838L NO20083838A NO20083838A NO20083838L NO 20083838 L NO20083838 L NO 20083838L NO 20083838 A NO20083838 A NO 20083838A NO 20083838 A NO20083838 A NO 20083838A NO 20083838 L NO20083838 L NO 20083838L
Authority
NO
Norway
Prior art keywords
symptoms
schizophrenia
relates
treat
reduce
Prior art date
Application number
NO20083838A
Other languages
English (en)
Inventor
Mario Rottlander
Daniel Rodriguez Greve
William Patrick Watson
Christian Wenzel Tornoe
Nikolay Khanzhin
Andreas Ritzen
Henriette Husum Bak-Jensen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38055396&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20083838(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NO20083838L publication Critical patent/NO20083838L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Oppfinnelsen vedrører en ny fremgangsmåte for behandling eller reduksjon av symptomer på schizofreni, der nevnte fremgangsmåte omfatter å administrere til en vert som trenger det en effektiv mengde av en forbindelse i stand til å selektivt øke ionestrømmen gjennom KCNQ-kaliumkanaler. Videre vedrører oppfinnelsen anvendelsen av selektive KCNQ-kaliumkanalåpnere for fremstillingen av en farmasøytisk sammensetning for behandling eller reduksjon av symptomer på schizofreni og beslektede symptomer, lidelser og sykdommer. Videre vedrører oppfinnelsen en fremgangsmåte for screening av en forbindelse, som er en selektiv KCNQ-kaliumkanalåpner og som er i stand til å ha et antipsykotisk potensial.
NO20083838A 2006-02-07 2008-09-05 Anvendelse av KCNQ-apnere for a behandle eller redusere symptomene pa schizofreni NO20083838L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77130406P 2006-02-07 2006-02-07
DKPA200600175 2006-02-07
PCT/DK2007/050013 WO2007090409A1 (en) 2006-02-07 2007-02-02 Use of kcnq-openers for threating or reducing the symptoms of schizophrenia

Publications (1)

Publication Number Publication Date
NO20083838L true NO20083838L (no) 2008-10-31

Family

ID=38055396

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083838A NO20083838L (no) 2006-02-07 2008-09-05 Anvendelse av KCNQ-apnere for a behandle eller redusere symptomene pa schizofreni

Country Status (16)

Country Link
US (1) US20090118285A1 (no)
EP (2) EP1983974A1 (no)
JP (1) JP2009525993A (no)
KR (1) KR20080096659A (no)
CN (1) CN101378742B (no)
AR (1) AR059319A1 (no)
AU (1) AU2007214128B2 (no)
BR (1) BRPI0707495A2 (no)
CA (1) CA2641564C (no)
EA (1) EA017915B1 (no)
IL (1) IL192745A0 (no)
MX (1) MX2008009655A (no)
NO (1) NO20083838L (no)
NZ (1) NZ569517A (no)
TW (1) TWI453013B (no)
WO (1) WO2007090409A1 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011513196A (ja) * 2007-08-01 2011-04-28 ハー・ルンドベック・アクチエゼルスカベット ドーパミン作動系が破壊された障害もしくは状態の症状を軽減するためまたはその障害もしくは状態を処置するためのｋｃｎｑカリウムチャネル開口薬の使用
CA2804165C (en) 2010-07-08 2015-02-24 Pfizer Inc. Piperidinyl pyrimidine amides as kv7 potassium channel openers
US10526280B2 (en) 2014-11-13 2020-01-07 University of Pittsburgh—of the Commonwealth System of Higher Education (2-amino-4-(arylamino)phenyl carbamates
US10590067B2 (en) 2018-02-20 2020-03-17 H. Lundbeck A/S Alcohol derivatives of carboxamides as Kv7 potassium channel openers
MD3755684T2 (ro) 2018-02-20 2023-11-30 H Lundbeck As Derivați de alcool ca deschizători ai canalelor de potasiu Kv7
WO2019203951A1 (en) 2018-04-20 2019-10-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Selective potassium channel agonists
JP2022543230A (ja) 2019-08-02 2022-10-11 ハー・ルンドベック・アクチエゼルスカベット てんかん又はてんかん発作において使用するためのＫｖ７カリウムチャネル開口薬としてのアルコール誘導体
AR119521A1 (es) 2019-08-02 2021-12-22 H Lundbeck As DERIVADOS DE ALCOHOL COMO ABRIDORES DEL CANAL DE POTASIO Kv7
CN114206830A (zh) 2019-08-02 2022-03-18 H.隆德贝克有限公司 作为Kv7钾通道开放剂的醇衍生物
CA3159876A1 (en) * 2019-12-06 2021-06-10 James MURROUGH Method of treatment with kcnq channel openers

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4200259A1 (de) * 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
JP4294142B2 (ja) 1999-02-02 2009-07-08 株式会社日立製作所 ディスクサブシステム
GB9915414D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
US6472165B1 (en) * 1999-08-03 2002-10-29 Arzneimittelwerk Dresden Gmbh Modulatory binding site in potassium channels for screening and finding new active ingredients
US6495550B2 (en) * 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
US6469042B1 (en) * 2001-02-20 2002-10-22 Bristol-Myers Squibb Company Fluoro oxindole derivatives as modulators if KCNQ potassium channels
EP1441722A2 (en) * 2001-02-20 2004-08-04 Bristol-Myers Squibb Company Modulators of kcnq potassium channels and use thereof in treating migraine and mechanistically related diseases
US6831080B2 (en) * 2001-05-31 2004-12-14 Bristol-Myers Squibb Company Cinnamide derivatives as KCNQ potassium channel modulators
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
WO2004047744A2 (en) * 2002-11-22 2004-06-10 Bristol-Myers Squibb Company 3-heterocyclic benzylamide derivatives as potassium channel openers
US6933308B2 (en) * 2002-12-20 2005-08-23 Bristol-Myers Squibb Company Aminoalkyl thiazole derivatives as KCNQ modulators
DK1578740T3 (da) * 2002-12-27 2007-07-30 Lundbeck & Co As H 1,2,4-triaminobenzenderivater, der er egnede til behandling af lidelser i centralnervesystemet
JP2006523196A (ja) * 2003-03-11 2006-10-12 ニューロサーチ、アクティーゼルスカブ 新規ｋｃｎｑチャネルを調節する化合物及びその医薬用途
AU2004220424B2 (en) * 2003-03-14 2009-01-22 H. Lundbeck A/S Substituted aniline derivatives
EP1613303A1 (en) 2003-03-21 2006-01-11 H. Lundbeck A/S Substituted p-diaminobenzene derivatives
US20060264496A1 (en) * 2003-04-25 2006-11-23 H. Lundbeck A/S Substituted indoline and indole derivatives
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
US7223768B2 (en) * 2003-09-10 2007-05-29 Icagen, Inc. Fused ring heterocycles as potassium channel modulators
JP4642034B2 (ja) * 2004-02-20 2011-03-02 ナショナル センター フォー バイオロジカル サイエンシズ 新規カリウムチャネルモジュレータペプチド
TWI349666B (en) * 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives
WO2006000020A1 (en) 2004-06-29 2006-01-05 European Nickel Plc Improved leaching of base metals
UA89503C2 (uk) * 2004-09-13 2010-02-10 Х. Луннбек А/С Заміщені похідні аніліну
EP1861394A1 (en) * 2005-03-03 2007-12-05 H.Lundbeck A/S Substituted pyridine derivatives
DE602006018447D1 (de) * 2005-04-13 2011-01-05 Neuraxon Inc Substituierte indolverbindungen mit nos-hemmender aktivität

Also Published As

Publication number Publication date
WO2007090409A1 (en) 2007-08-16
TWI453013B (zh) 2014-09-21
NZ569517A (en) 2011-07-29
EP1983974A1 (en) 2008-10-29
MX2008009655A (es) 2008-09-03
EA017915B1 (ru) 2013-04-30
AR059319A1 (es) 2008-03-26
CN101378742A (zh) 2009-03-04
US20090118285A1 (en) 2009-05-07
CA2641564C (en) 2012-06-12
AU2007214128B2 (en) 2012-05-17
CN101378742B (zh) 2013-07-10
IL192745A0 (en) 2009-02-11
BRPI0707495A2 (pt) 2011-05-03
EA200870232A1 (ru) 2009-02-27
TW200808296A (en) 2008-02-16
JP2009525993A (ja) 2009-07-16
AU2007214128A1 (en) 2007-08-16
CA2641564A1 (en) 2007-08-16
EP2554162A1 (en) 2013-02-06
KR20080096659A (ko) 2008-10-31

Similar Documents

Publication Publication Date Title
NO20083838L (no) Anvendelse av KCNQ-apnere for a behandle eller redusere symptomene pa schizofreni
NO341523B1 (no) Benzoimidazol-2-ylpyrimidiner og -pyraziner som modulatorer av histamin H4-reseptoren, farmasøytisk sammensetning samt anvendelse
PT1543011E (pt) Composto de tienopirrolilo e furanopirrolilo e sua utilizacao como ligandos do receptor h4 da histamina
CY1121135T1 (el) Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος
EA201070189A1 (ru) Применение соединений, открывающих калиевые каналы kcnq, для подавления симптомов или лечения расстройств или состояний, при которых нарушается дофаминергическая система
TR201819564T4 (tr) Cmt ve ilgili bozuklukların tedavisi için yeni terapötik yaklaşımlar.
NO20082923L (no) Anvendelse av en CB1 antagonist for behandling av bivirkninger og negative symptomer pa schizofreni
DK1937669T3 (da) Nye benzopyranderivater som kaliumkanalåbnere
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
MX2007012353A (es) Metodos para el tratamiento de alteraciones relacionadas con la ansiedad.
WO2007087468A3 (en) Adiponectin for treatment of various disorders
ATE479678T1 (de) Benzoimidazol-2-yl pyridine als modulatoren des histamin-h4-rezeptors
SG179410A1 (en) Therapeutic uses of inhibitors of rtp801
EA200700262A1 (ru) Арилидены для лечения заболеваний, опосредуемых эстроген-родственным рецепторам альфа
NO20074959L (no) Substituerte pyridinderivater
NO20084374L (no) Imidazoltiazolforbindelser for behandling av sykdom
NO20065984L (no) Forbindelser og sammensetninger som PPAR modulatorer
WO2004066987A3 (en) Use of sodium channel modulators for treating gastrointestinal tract disorders
MY145349A (en) Benzofuro- and benzothienopyrimidine modulators of the histamine h4 receptor
NO20065983L (no) Forbindelser og sammensetninger som PPAR modulatorer
BRPI0506970B8 (pt) derivados de alfa-aminoamida úteis no tratamento de distúrbios do trato urinário inferior
MX2009005725A (es) Metodos y composiciones para tratamiento y monitoreo de tratamiento de trastornos asociados con il-13.
UA96447C2 (ru) Полиморфные формы (2s)-(4e)-n-метил-5-[3-(5-изопропоксипиридин)ил]-4-пентен-2-амина для лечения расстройств центральной нервной системы
NO20092073L (no) Modulatorer av C3A-reseptor, og fremgangsmater for anvendelse derav
NO20083751L (no) Metoder for behandling av kognitive og andre sykdommer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application